Teplizumab Side Effects
Medically reviewed by Drugs.com. Last updated on Mar 22, 2025.
Applies to teplizumab: intravenous solution.
Serious side effects of teplizumab
Along with its needed effects, teplizumab may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor or nurse immediately if any of the following side effects occur while taking teplizumab:
More common side effects
- black, tarry stools
- bleeding gums
- blood in the urine or stools
- chest pain or tightness
- cough or hoarseness
- dizziness
- fever or chills
- headache
- itching, pain, redness, swelling, tenderness, or warmth on the skin
- loss of appetite
- lower back or side pain
- muscle aches or pain
- nausea
- painful or difficult urination
- pale skin
- pinpoint red spots on the skin
- rash
- red, tender, or oozing skin at the incision
- sneezing
- sore throat
- sores, ulcers, or white spots on the lips or in the mouth
- stomach pain
- stuffy or runny nose
- swollen glands
- trouble breathing
- unusual bleeding or bruising
- unusual tiredness or weakness
Less common side effects
- diarrhea
- difficulty swallowing
- faintness
- fast heartbeat
- general feeling of discomfort or illness
- joint pain or swelling
- muscle pain
- puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
- vomiting
Rare side effects
- large, hive-like swelling on face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs
For healthcare professionals
Applies to teplizumab: intravenous solution.
Dermatologic adverse events
- Very common (10% or more): Rash (48%)
- Common (1% to 10%): Urticaria
- Uncommon (0.1% to 1%): Angioedema[Ref]
Gastrointestinal
- Common (1% to 10%): Diarrhea, nausea[Ref]
Hematologic
- Very common (10% or more): Anemia (27%), leukopenia (21%), lymphopenia (74%), thrombocytopenia (13%)
- Common (1% to 10%): Neutropenia[Ref]
Hepatic
- Common (1% to 10%): Increased alanine aminotransferase[Ref]
Hypersensitivity
- Common (1% to 10%): Cytokine Release Syndrome (CRS)[Ref]
Immunologic
- Common (1% to 10%): Serum sickness[Ref]
Metabolic
- Very common (10% or more): Liver transaminase elevations (56%)[Ref]
In patients treated with this drug who experienced CRS, 56% of them reported increased liver transaminase levels: 64% were up to 2.5 times upper limit of normal (ULN), 32% were more than 2.5 to 5 times ULN, and 4.5% were 5-10 times ULN.[Ref]
Other
- Very common (10% or more): Decreased bicarbonate (15%), decreased blood calcium (19%)
- Common (1% to 10%): Serious infection
- Uncommon (0.1% to 1%): Peripheral and generalized edema[Ref]
Respiratory
- Common (1% to 10%): Nasopharyngitis[Ref]
Nervous system
- Very common (10% or more): Headache (11%)[Ref]
References
1. (2022) "Product Information. Tzield (teplizumab)." Provention Bio, Inc.
Frequently asked questions
More about teplizumab
- Check interactions
- Compare alternatives
- Dosage information
- During pregnancy
- Drug class: miscellaneous antidiabetic agents
- Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Further information
Teplizumab side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.
